Glybera, the gene therapy which is the most expensive drug in the world, is to be withdrawn from the market because it has proven to be a commercial failure. Amsterdam-headquartered firm uniQure ...

Thank you for taking time to provide your feedback to the editors. Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

The only other gene therapies to have made it to market so far are uniQure’s Glybera’s (alipogene tiparvovec), and GSK’s Strimvelis, but both have only gained EU approval. Glybera is a case ...